 Elizabeth Redente
Concepts (272)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pulmonary Fibrosis | 14 | 2024 | 384 | 3.550 |
Why?
| | Idiopathic Pulmonary Fibrosis | 13 | 2025 | 633 | 2.980 |
Why?
| | Lung | 24 | 2024 | 3927 | 1.690 |
Why?
| | Macrophages, Alveolar | 8 | 2025 | 389 | 1.480 |
Why?
| | Bleomycin | 14 | 2024 | 242 | 1.390 |
Why?
| | Fibroblasts | 12 | 2025 | 948 | 1.380 |
Why?
| | fas Receptor | 4 | 2020 | 95 | 0.920 |
Why?
| | Alveolar Epithelial Cells | 7 | 2023 | 106 | 0.900 |
Why?
| | Lung Injury | 5 | 2024 | 210 | 0.870 |
Why?
| | Signal Transduction | 11 | 2021 | 4926 | 0.850 |
Why?
| | Silicosis | 1 | 2023 | 27 | 0.800 |
Why?
| | Collagen | 5 | 2019 | 433 | 0.740 |
Why?
| | Mice | 35 | 2024 | 16915 | 0.720 |
Why?
| | Cytoskeletal Proteins | 1 | 2021 | 146 | 0.700 |
Why?
| | Arthritis, Experimental | 3 | 2018 | 135 | 0.700 |
Why?
| | Lung Diseases, Interstitial | 3 | 2023 | 610 | 0.690 |
Why?
| | Transforming Growth Factor beta | 6 | 2020 | 455 | 0.680 |
Why?
| | Lung Diseases | 3 | 2023 | 739 | 0.680 |
Why?
| | Monocytes | 5 | 2023 | 551 | 0.670 |
Why?
| | Animals | 46 | 2025 | 35309 | 0.650 |
Why?
| | ATP-Binding Cassette Transporters | 1 | 2020 | 133 | 0.630 |
Why?
| | Respiratory Mucosa | 3 | 2025 | 307 | 0.620 |
Why?
| | Indoles | 2 | 2019 | 384 | 0.600 |
Why?
| | Cell Separation | 2 | 2019 | 316 | 0.560 |
Why?
| | Epithelial Cells | 4 | 2023 | 1063 | 0.550 |
Why?
| | Macrophages | 8 | 2024 | 1484 | 0.550 |
Why?
| | X-Ray Microtomography | 3 | 2023 | 83 | 0.520 |
Why?
| | Apoptosis | 6 | 2023 | 2499 | 0.520 |
Why?
| | Wnt Signaling Pathway | 1 | 2017 | 170 | 0.470 |
Why?
| | Serum Response Factor | 1 | 2015 | 31 | 0.470 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2024 | 1202 | 0.460 |
Why?
| | Mesoderm | 1 | 2015 | 137 | 0.440 |
Why?
| | Disease Models, Animal | 11 | 2024 | 4057 | 0.440 |
Why?
| | Mice, Inbred C57BL | 13 | 2024 | 5439 | 0.440 |
Why?
| | Flow Cytometry | 4 | 2020 | 1155 | 0.440 |
Why?
| | Lung Neoplasms | 6 | 2018 | 2342 | 0.400 |
Why?
| | Pneumonia | 4 | 2023 | 616 | 0.400 |
Why?
| | Trans-Activators | 1 | 2015 | 388 | 0.390 |
Why?
| | Cell Polarity | 2 | 2010 | 139 | 0.390 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2024 | 232 | 0.390 |
Why?
| | Interferon-gamma | 3 | 2010 | 772 | 0.390 |
Why?
| | Lipid Metabolism | 2 | 2025 | 497 | 0.370 |
Why?
| | Mice, Knockout | 10 | 2020 | 2871 | 0.360 |
Why?
| | Pulmonary Alveoli | 3 | 2025 | 400 | 0.350 |
Why?
| | Disease Progression | 3 | 2021 | 2630 | 0.330 |
Why?
| | Bone Marrow Cells | 1 | 2010 | 302 | 0.310 |
Why?
| | Cells, Cultured | 9 | 2020 | 4077 | 0.300 |
Why?
| | Fibrosis | 4 | 2024 | 520 | 0.290 |
Why?
| | Adenoma | 2 | 2007 | 214 | 0.290 |
Why?
| | Receptors, Cell Surface | 1 | 2009 | 380 | 0.280 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 2 | 2020 | 23 | 0.280 |
Why?
| | Urethane | 1 | 2007 | 41 | 0.270 |
Why?
| | Carcinogens | 1 | 2007 | 110 | 0.260 |
Why?
| | Melanoma, Experimental | 2 | 2018 | 107 | 0.240 |
Why?
| | Bone Marrow | 1 | 2007 | 271 | 0.240 |
Why?
| | Humans | 29 | 2025 | 129271 | 0.230 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2007 | 327 | 0.230 |
Why?
| | Lung Compliance | 3 | 2014 | 46 | 0.230 |
Why?
| | Single-Cell Analysis | 3 | 2024 | 275 | 0.230 |
Why?
| | Keratin-8 | 1 | 2023 | 4 | 0.220 |
Why?
| | Pulmonary Alveolar Proteinosis | 1 | 2024 | 17 | 0.220 |
Why?
| | Granulomatous Disease, Chronic | 1 | 2024 | 53 | 0.220 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2024 | 86 | 0.220 |
Why?
| | Endoribonucleases | 1 | 2024 | 73 | 0.210 |
Why?
| | Fluorescent Antibody Technique | 2 | 2018 | 376 | 0.210 |
Why?
| | Adenocarcinoma | 2 | 2009 | 898 | 0.210 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2024 | 101 | 0.210 |
Why?
| | Folate Receptor 2 | 1 | 2023 | 9 | 0.210 |
Why?
| | Fibroblast Growth Factor 10 | 2 | 2019 | 23 | 0.200 |
Why?
| | Biomarkers, Tumor | 2 | 2020 | 1173 | 0.200 |
Why?
| | Membrane Glycoproteins | 1 | 2024 | 476 | 0.190 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2023 | 182 | 0.190 |
Why?
| | Biomarkers | 3 | 2024 | 3968 | 0.190 |
Why?
| | Acute Lung Injury | 2 | 2017 | 279 | 0.190 |
Why?
| | Male | 21 | 2024 | 63517 | 0.190 |
Why?
| | Proline | 1 | 2021 | 76 | 0.180 |
Why?
| | Regeneration | 2 | 2019 | 181 | 0.170 |
Why?
| | Neoplasms, Experimental | 1 | 2020 | 170 | 0.170 |
Why?
| | Multimodal Imaging | 1 | 2020 | 110 | 0.160 |
Why?
| | Bronchoalveolar Lavage Fluid | 3 | 2011 | 644 | 0.160 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2019 | 24 | 0.160 |
Why?
| | Interleukin-4 | 2 | 2010 | 212 | 0.160 |
Why?
| | Protein Tyrosine Phosphatase, Non-Receptor Type 13 | 1 | 2018 | 7 | 0.150 |
Why?
| | Gene Deletion | 2 | 2018 | 380 | 0.150 |
Why?
| | Mice, Transgenic | 4 | 2019 | 2117 | 0.150 |
Why?
| | Pulmonary Surfactant-Associated Proteins | 1 | 2018 | 10 | 0.150 |
Why?
| | Extracellular Matrix | 2 | 2019 | 502 | 0.150 |
Why?
| | CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2018 | 21 | 0.140 |
Why?
| | CD11 Antigens | 1 | 2018 | 30 | 0.140 |
Why?
| | Imaging, Three-Dimensional | 1 | 2021 | 529 | 0.140 |
Why?
| | Lipopolysaccharides | 4 | 2024 | 877 | 0.140 |
Why?
| | Adaptive Immunity | 1 | 2018 | 161 | 0.140 |
Why?
| | Myofibroblasts | 1 | 2018 | 121 | 0.140 |
Why?
| | Macrophage Activation | 2 | 2009 | 189 | 0.140 |
Why?
| | Immunoglobulin M | 1 | 2018 | 276 | 0.140 |
Why?
| | Homeostasis | 1 | 2020 | 605 | 0.130 |
Why?
| | Phospholipases A2 | 1 | 2016 | 79 | 0.130 |
Why?
| | Lung Diseases, Fungal | 1 | 2016 | 13 | 0.130 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2018 | 374 | 0.130 |
Why?
| | Candida albicans | 1 | 2016 | 53 | 0.130 |
Why?
| | Candidiasis | 1 | 2016 | 56 | 0.130 |
Why?
| | CD11b Antigen | 1 | 2016 | 60 | 0.130 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2016 | 60 | 0.130 |
Why?
| | Antigens, Neoplasm | 1 | 2018 | 308 | 0.130 |
Why?
| | Lipids | 3 | 2024 | 625 | 0.130 |
Why?
| | Phagocytes | 1 | 2016 | 97 | 0.120 |
Why?
| | Neoplasms | 1 | 2010 | 2449 | 0.120 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1688 | 0.120 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 274 | 0.120 |
Why?
| | Dendritic Cells | 1 | 2018 | 479 | 0.120 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2020 | 756 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2021 | 1117 | 0.120 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2018 | 857 | 0.120 |
Why?
| | Stem Cells | 1 | 2019 | 574 | 0.120 |
Why?
| | Receptor, Macrophage Colony-Stimulating Factor | 1 | 2014 | 9 | 0.110 |
Why?
| | Hydroxyproline | 1 | 2014 | 21 | 0.110 |
Why?
| | Mice, Inbred BALB C | 3 | 2016 | 1247 | 0.110 |
Why?
| | Tacrolimus Binding Proteins | 1 | 2014 | 27 | 0.110 |
Why?
| | Arthritis, Rheumatoid | 2 | 2013 | 1097 | 0.110 |
Why?
| | Antigens, CD | 1 | 2016 | 489 | 0.110 |
Why?
| | Remission Induction | 1 | 2014 | 271 | 0.100 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2013 | 66 | 0.100 |
Why?
| | Female | 13 | 2019 | 68556 | 0.100 |
Why?
| | Wound Healing | 2 | 2017 | 306 | 0.100 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2018 | 1056 | 0.100 |
Why?
| | Mice, Inbred Strains | 2 | 2010 | 406 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2012 | 172 | 0.090 |
Why?
| | Leukocytes | 1 | 2013 | 306 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 833 | 0.090 |
Why?
| | Chemokine CXCL1 | 1 | 2011 | 72 | 0.090 |
Why?
| | Cytokines | 5 | 2024 | 2013 | 0.090 |
Why?
| | Pyridones | 1 | 2012 | 159 | 0.090 |
Why?
| | Up-Regulation | 2 | 2011 | 839 | 0.090 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 104 | 0.090 |
Why?
| | Colonic Neoplasms | 1 | 2013 | 242 | 0.090 |
Why?
| | Neutrophils | 1 | 2016 | 1207 | 0.090 |
Why?
| | Schistosoma mansoni | 1 | 2010 | 37 | 0.090 |
Why?
| | Butylated Hydroxytoluene | 1 | 2010 | 38 | 0.080 |
Why?
| | Schistosomiasis | 1 | 2010 | 47 | 0.080 |
Why?
| | Granuloma | 1 | 2010 | 89 | 0.080 |
Why?
| | Recovery of Function | 1 | 2014 | 641 | 0.080 |
Why?
| | Sex Characteristics | 2 | 2013 | 736 | 0.080 |
Why?
| | Testosterone | 1 | 2013 | 372 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 338 | 0.080 |
Why?
| | Interleukin-13 | 1 | 2010 | 147 | 0.080 |
Why?
| | Immunoenzyme Techniques | 1 | 2009 | 214 | 0.080 |
Why?
| | Antigens | 1 | 2011 | 356 | 0.080 |
Why?
| | Hepatocyte Growth Factor | 2 | 2019 | 34 | 0.080 |
Why?
| | Intubation, Intratracheal | 1 | 2011 | 239 | 0.080 |
Why?
| | Immunity, Innate | 2 | 2016 | 803 | 0.080 |
Why?
| | Lymph Nodes | 1 | 2011 | 470 | 0.070 |
Why?
| | Nanoparticles | 1 | 2012 | 375 | 0.070 |
Why?
| | Protein Kinase Inhibitors | 2 | 2019 | 890 | 0.070 |
Why?
| | Sex Factors | 2 | 2011 | 1965 | 0.070 |
Why?
| | Autoimmunity | 1 | 2013 | 862 | 0.070 |
Why?
| | Angiogenesis Inhibitors | 1 | 2009 | 220 | 0.070 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 296 | 0.070 |
Why?
| | Tuberculosis | 1 | 2010 | 273 | 0.070 |
Why?
| | Survival Rate | 1 | 2011 | 1869 | 0.070 |
Why?
| | Nitric Oxide Synthase Type II | 1 | 2007 | 171 | 0.070 |
Why?
| | Cell Line | 3 | 2019 | 2779 | 0.060 |
Why?
| | Quinazolines | 1 | 2007 | 244 | 0.060 |
Why?
| | Mast Cells | 1 | 2007 | 142 | 0.060 |
Why?
| | Rats | 3 | 2019 | 5482 | 0.060 |
Why?
| | Eye Proteins | 1 | 2024 | 88 | 0.060 |
Why?
| | ErbB Receptors | 1 | 2007 | 605 | 0.060 |
Why?
| | Chronic Disease | 1 | 2010 | 1716 | 0.050 |
Why?
| | Wounds and Injuries | 1 | 2010 | 711 | 0.050 |
Why?
| | Age Factors | 1 | 2011 | 3140 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 2024 | 110 | 0.050 |
Why?
| | NADPH Oxidases | 1 | 2024 | 108 | 0.050 |
Why?
| | Time Factors | 1 | 2014 | 6543 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2023 | 2515 | 0.050 |
Why?
| | Genetic Predisposition to Disease | 1 | 2010 | 2276 | 0.050 |
Why?
| | Phosphorylation | 2 | 2020 | 1710 | 0.050 |
Why?
| | Photoacoustic Techniques | 1 | 2020 | 5 | 0.040 |
Why?
| | Reproducibility of Results | 2 | 2019 | 3080 | 0.040 |
Why?
| | Cell Proliferation | 3 | 2017 | 2375 | 0.040 |
Why?
| | Phenotype | 2 | 2019 | 3074 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2018 | 2703 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 428 | 0.040 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2020 | 77 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1691 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 286 | 0.040 |
Why?
| | Gene Expression Regulation | 2 | 2018 | 2537 | 0.040 |
Why?
| | Hypertension, Pulmonary | 1 | 2010 | 1894 | 0.040 |
Why?
| | Fibroblast Growth Factor 7 | 1 | 2018 | 15 | 0.040 |
Why?
| | CD40 Ligand | 1 | 2018 | 38 | 0.040 |
Why?
| | Scleroderma, Systemic | 1 | 2019 | 114 | 0.040 |
Why?
| | Culture Media, Serum-Free | 1 | 2018 | 49 | 0.040 |
Why?
| | Drug Resistance, Microbial | 1 | 2018 | 69 | 0.040 |
Why?
| | Pulmonary Surfactants | 1 | 2019 | 106 | 0.040 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 74 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2019 | 160 | 0.040 |
Why?
| | Antigen-Presenting Cells | 1 | 2018 | 151 | 0.040 |
Why?
| | Pilot Projects | 1 | 2023 | 1584 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2019 | 141 | 0.040 |
Why?
| | Biopsy, Needle | 1 | 2018 | 189 | 0.040 |
Why?
| | T-Lymphocytes, Helper-Inducer | 1 | 2018 | 135 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2019 | 216 | 0.040 |
Why?
| | Lipogenesis | 1 | 2018 | 59 | 0.040 |
Why?
| | Inflammation | 2 | 2023 | 2737 | 0.030 |
Why?
| | Chemokine CXCL12 | 1 | 2017 | 79 | 0.030 |
Why?
| | Receptors, CXCR4 | 1 | 2017 | 83 | 0.030 |
Why?
| | Permeability | 1 | 2017 | 157 | 0.030 |
Why?
| | Reference Values | 1 | 2018 | 793 | 0.030 |
Why?
| | Antineoplastic Agents | 1 | 2007 | 2054 | 0.030 |
Why?
| | Eicosanoids | 1 | 2016 | 57 | 0.030 |
Why?
| | Arachidonic Acid | 1 | 2016 | 115 | 0.030 |
Why?
| | RNA, Small Interfering | 1 | 2018 | 591 | 0.030 |
Why?
| | Down-Regulation | 1 | 2018 | 636 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2023 | 1887 | 0.030 |
Why?
| | Anti-Inflammatory Agents | 1 | 2019 | 480 | 0.030 |
Why?
| | Organ Specificity | 1 | 2016 | 295 | 0.030 |
Why?
| | Societies, Medical | 1 | 2019 | 744 | 0.030 |
Why?
| | Lymphocyte Activation | 1 | 2018 | 1109 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2017 | 530 | 0.030 |
Why?
| | Smad Proteins | 1 | 2014 | 38 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2016 | 367 | 0.030 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2014 | 56 | 0.030 |
Why?
| | NIH 3T3 Cells | 1 | 2014 | 140 | 0.030 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2013 | 44 | 0.030 |
Why?
| | Disease Resistance | 1 | 2013 | 31 | 0.030 |
Why?
| | Genes, Reporter | 1 | 2014 | 265 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2016 | 505 | 0.030 |
Why?
| | Adenoviridae | 1 | 2014 | 192 | 0.030 |
Why?
| | Polyglactin 910 | 1 | 2012 | 6 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2013 | 256 | 0.030 |
Why?
| | Bronchoalveolar Lavage | 1 | 2012 | 92 | 0.020 |
Why?
| | Tumor Burden | 1 | 2013 | 286 | 0.020 |
Why?
| | Cell Movement | 1 | 2016 | 944 | 0.020 |
Why?
| | Instillation, Drug | 1 | 2011 | 9 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2019 | 1497 | 0.020 |
Why?
| | Fas Ligand Protein | 1 | 2011 | 59 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 297 | 0.020 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2013 | 231 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2011 | 140 | 0.020 |
Why?
| | Gene Expression | 1 | 2016 | 1466 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3377 | 0.020 |
Why?
| | Smad3 Protein | 1 | 2010 | 43 | 0.020 |
Why?
| | Smad2 Protein | 1 | 2010 | 38 | 0.020 |
Why?
| | Smoke | 1 | 2011 | 139 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 635 | 0.020 |
Why?
| | Tumor Microenvironment | 1 | 2013 | 631 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2009 | 124 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3386 | 0.020 |
Why?
| | Immunoblotting | 1 | 2009 | 305 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2010 | 610 | 0.020 |
Why?
| | Microvessels | 1 | 2009 | 82 | 0.020 |
Why?
| | Injections, Intraperitoneal | 1 | 2007 | 111 | 0.020 |
Why?
| | Erlotinib Hydrochloride | 1 | 2007 | 70 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1204 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2014 | 1416 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2010 | 1288 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2013 | 1344 | 0.020 |
Why?
| | Transcriptome | 1 | 2013 | 874 | 0.020 |
Why?
| | Silymarin | 1 | 2009 | 199 | 0.020 |
Why?
| | STAT3 Transcription Factor | 1 | 2009 | 194 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2018 | 7055 | 0.020 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2007 | 259 | 0.020 |
Why?
| | Retrospective Studies | 1 | 2023 | 14461 | 0.020 |
Why?
| | Aged | 2 | 2018 | 22032 | 0.020 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2010 | 625 | 0.020 |
Why?
| | NF-kappa B | 1 | 2009 | 665 | 0.010 |
Why?
| | Longitudinal Studies | 1 | 2011 | 2716 | 0.010 |
Why?
| | Middle Aged | 2 | 2018 | 31091 | 0.010 |
Why?
| | Models, Biological | 1 | 2010 | 1722 | 0.010 |
Why?
| | Body Weight | 1 | 2007 | 939 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2007 | 2011 | 0.010 |
Why?
| | United States | 1 | 2019 | 13828 | 0.010 |
Why?
| | Prospective Studies | 1 | 2011 | 7123 | 0.010 |
Why?
| | Mutation | 1 | 2007 | 3710 | 0.010 |
Why?
|
|
Redente's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|